What are Birgit Girshick’s remaining CRL share holdings after these transactions?

After these transactions, Birgit Girshick is reported to have 43,803 CRL common shares held indirectly through a revocable trust, according to the Form 4 holding entry.

Charles River CEO exercises options and sells shares

Q: What did CRL CEO Birgit Girshick report in this Form 4 transaction?

Birgit Girshick exercised options for 6,500 CRL shares at $179.66 and sold 6,500 shares at $279.90 on August 11, 2026, with the transactions reported under a Rule 10b5-1 Trading Plan.

Q: At what prices were the CRL shares exercised and sold in this Form 4?

The options were exercised at $179.66 per share, and the resulting common shares were sold at $279.90 per share, both on August 11, 2026, as disclosed for Charles River Laboratories (CRL).

Q: How many Charles River Laboratories (CRL) shares did the CEO sell?

The CEO, Birgit Girshick, sold 6,500 shares of CRL common stock on August 11, 2026, following the exercise of an equal number of stock options into common shares.

Q: Were the CRL insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale occurred under a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025, indicating the trades were pre-arranged.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Chief Executive Officer Birgit Girshick exercised stock options for 6,500 shares of common stock on August 11, 2026 at an exercise price of $179.66 per share. The resulting 6,500 common shares were then sold at $279.90 per share on the same date, in a transaction marked as a sale. The company reports that this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 3, 2025. Following these transactions, Girshick has an indirect holding of 43,803 common shares through a revocable trust.

Insider Trade Summary 10b5-1

Exercise and Sale: 6,500 shares ($652K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Girshick Birgit

Role Chief Executive Officer

Sold 6,500 shs ($1.82M)

Approx. gross sale proceeds $1.82M

Approx. exercise cost $1.17M

Approx. pre-tax spread $652K

Type	Security	Shares	Price	Value
Exercise	Stock Options (Right to Buy)	6,500	$0.00	$0.00
Exercise	Common Stock	6,500	$179.66	$1.17M
Sale	Common Stock ^F1	6,500	$279.90	$1.82M
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (Right to Buy) — 0 contracts (Direct); Common Stock — 36,013 shares (Direct); Common Stock — 43,803 shares (Indirect, Revocable Trust)

Footnotes (1)

F1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025.

Key Figures

Options Exercised: 6,500 shares Exercise Price: $179.66 per share Shares Sold: 6,500 shares +2 more

5 metrics

Options Exercised 6,500 shares Stock options exercised into common stock on August 11, 2026

Exercise Price $179.66 per share Exercise price of stock options converted into 6,500 common shares

Shares Sold 6,500 shares Common stock sold on August 11, 2026

Sale Price $279.90 per share Per-share price of 6,500 common shares sold

Indirect Holdings After Transaction 43,803 shares Common stock held indirectly through a revocable trust after reported transactions

Key Terms

Rule 10b5-1 Trading Plan, Stock Options (Right to Buy), Revocable Trust

3 terms

Rule 10b5-1 Trading Plan regulatory

"This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Options (Right to Buy) financial

"security_title: Stock Options (Right to Buy)"

Revocable Trust financial

"nature_of_ownership: Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRL CEO Birgit Girshick report in this Form 4 transaction?

Birgit Girshick exercised options for 6,500 CRL shares at $179.66 and sold 6,500 shares at $279.90 on August 11, 2026, with the transactions reported under a Rule 10b5-1 Trading Plan.

At what prices were the CRL shares exercised and sold in this Form 4?

The options were exercised at $179.66 per share, and the resulting common shares were sold at $279.90 per share, both on August 11, 2026, as disclosed for Charles River Laboratories (CRL).

How many Charles River Laboratories (CRL) shares did the CEO sell?

The CEO, Birgit Girshick, sold 6,500 shares of CRL common stock on August 11, 2026, following the exercise of an equal number of stock options into common shares.

Were the CRL insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale occurred under a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025, indicating the trades were pre-arranged.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/13/2026 - 04:38 PM EDT Accepted by SEC EDGAR 08/13/2026 - 04:37 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girshick Birgit

(Last)

(First)

(Middle)

C/O CHARLES RIVER LABORATORIES

251 BALLARDVALE STREET

(Street)

WILMINGTON

MASSACHUSETTS

01887

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. [ CRL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/11/2026		M		6,500	A	$179.66	42,513	D
Common Stock	08/11/2026		S		6,500⁽¹⁾	D	$279.9	36,013	D
Common Stock								43,803	I	Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$179.66	08/11/2026		M			6,500	05/29/2021	05/29/2030	Common Stock	6,500	$0	0	D

Explanation of Responses:

1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025.

	/s/ Birgit Girshick	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR